About Us
About Guard Therapeutics
Vision, Business Model & Goal
The Board
Management
Research
Kidney disease
Science
Pipeline
RMC-035
GTX Peptides
Investor Relations
Financial calender
Financial reports
Share information
Corporate governance
General meetings
Rights Issue 2025
Newsroom
Press releases
Event calender
Analyses and presentations
Subscribe
Contact
Swe
Search
Novel Therapies Targeting Kidney Disease
Latest Press Releases
Guard Therapeutics announces changes in number of shares and votes
(regulatory)
Read more
Guard Therapeutics announces outcome of the rights issue
(regulatory)
Read more
Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study
Read more
Press releases
11 Apr 2025 · Regulatory information
Guard Therapeutics announces changes in number of shares and votes
Read more
04 Apr 2025 · Regulatory information
Guard Therapeutics announces outcome of the rights issue
Read more
25 Mar 2025
Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study
Read more
19 Mar 2025 · Regulatory information
Guard Therapeutics publishes information document regarding rights issue
Read more
Show more
In focus
17 Oct 2024 / Presentation
Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"
Read more
23 Sep 2024 / Presentation
CEO Tobias Agervald appears on BiotechTV
Read more
19 Sep 2024 / Presentation
Presentation at Pareto Securities' 15th Annual Healthcare Conference
Read more
30 Jan 2024 / Presentation
Guard Therapeutics R&D update January 30, 2024
Read more
Show more
Upcoming events
05 May 2025
Interim report January-March 2025
Read more
15 May 2025
Annual General Meeting 2025
Read more
04 Jun 2025
Guard attends the 62nd ERA Congress, Vienna, June 4-7
Read more
16 Jun 2025
Guard attends the Bio International, Boston, June 16-19
Read more
Show more
Event calendar
/
Financial calendar